IntroductionAt a recent conference, Dr. Anjali Advani of the Cleveland Clinic discussed the transformative role of Chimeric Antigen Receptor T-cell…
Browsing: Acute Lymphoblastic Leukemia
Introduction to Emerging Therapies in ALL Management…Dr. Elias Jabbour shared recent developments in the treatment of acute lymphoblastic leukemia (ALL)…
…The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in combination with chemotherapy represents a significant…
OverviewThe U.S. Food and Drug Administration (FDA) has granted approval for the use of inotuzumab ozogamicin (Besponsa, Pfizer) in pediatric…
In 2024, CAR T-cell therapy continues to transform the landscape of treatment for hematologic malignancies, including multiple myeloma and various…
Evandro Bezerra, MD, hematologist and assistant professor at The Ohio State University Wexner Medical Center, leads research focused on improving…
By: Ibrahim Aldoss, MD – City of HopeDate: 12/11/2023Revumenib Monotherapy in KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from…
Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, shared her insights during a discussion with Allen Wilbanks…
Ticiana Leal, MD, is at the forefront of an intriguing and evolving discussion centered on the mechanism underlying tumor treating…
Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour,…
Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell…
Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, delves…
Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD expresses…
Shira N. Dinner, MD- Robert H Lurie Cancer Center Shira N. Dinner, MD discussed several studies focused on the treatment…
Hagop Kantarjian, MD is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer…
Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer…
Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell…
Marina Konopleva, MD, PhD – University of Texas MD Anderson Cancer Center and Albert Einstein College of Medicine Jack and…
Marlise Luskin,MD, MSCE- Medical Oncology- Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program and education director for the adult leukemia program. The…
Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD…
Ryan D. Cassaday,MD- Physician-Fred Hutch Ryan Cassaday, MD emphasizes the importance of the topic at hand and humorously compares the…
Anjali Advani, MD- Hematology and Medical Oncology- Cleveland Clinic Anjali Advani, MD, begins her talk by expressing gratitude for the…
Aaron Logan, MD, PhD- Associate Professor of Clinical Medicine, Division of Hematology/Oncology, UCSF Aaron Logan, MD PhD, conveyed his gratitude…
Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, expresses gratitude…
Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX The talk, delivered…
Wendy Stock, MD – Anjuli Seth Nayak Professor of Medicine- The University of Chicago Medicine In this presentation, Wendy Stock,…
For those with an interest in the management of acute myeloid leukemia, the conference provided a unique and valuable platform.…
The discussion revolves around the complexities of Blinatumomab treatment for leukemia, with experts debating the reasons behind the partial clinical…
In this lively debate, experts engage in a comprehensive analysis of Nelarabine’s efficacy in the treatment of ALL. The discussion…
In a dynamic and insightful debate, leading experts in the field of leukemia treatment delved into the intricacies of optimizing…
Harry Paul Erba, MD Professor of Medicine and Member of the Duke Cancer Institute Harry Erba, MD, a respected Duke…
Marlise R. Luskin, MD, MSCE is a physician in Dana-Farber’s Adult Leukemia program. Meet Marlise Luskin, MD, MSCE, an esteemed…
Nitin Jain, MD. Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,…
Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD, MSCE…
Hagop M. Kantarjian, MD. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,…
Bijal Shah, MD, MS Hematology/Oncology H. Lee Moffic Cancer Center In the video, Bijal Shah, MD, MS discusses the significance…
Aaron Logan, MD – Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF) Meet Aaron…
Anju Replacement
Today we talk about a topic that has been stirring considerable interest in the oncology field, promising an innovative approach…
Dr. Timothy Cloughesy, a prominent physician from UCLA Health, conducted the INDIGO clinical trial to evaluate the efficacy of Vorasidenib,…
HPV Advances: Jill Meyer-Lippert, Dr. Jared Weiss, and Dr. Mary Cooley give an in-depth examination of HPV+ head and neck…
Lisaftoclax (APG-2575): In CLL / SLL Treatment: Safety and Efficacy as Monotherapy or Combined with Acalabrutinib or Rituximab Matthew Davids…
MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at…
Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia…
iFrame is not supported! Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the…
iFrame is not supported! CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP,…
TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from…
iFrame is not supported! TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the…
iFrame is not supported! Biomarkers: Breast Cancer – Daniel Rotroff SABCS 2022 GENIE Trial What will help identify (biomarkers)…
Blinatumomab: ECOG-ACRIN E1910 National Clinical Trials Network Clinical trial By Mark Litzow, MD ECOG-ACRIN E1910 National Clinical Trials Network Clinical…
iFrame is not supported! IDE196 Solid Tumors GNAQ/11 Mutations or PRKC Fusions [2022] What is IDE196? And How Will It…
iFrame is not supported! Lung SBRT Dose Optimization [2022]: Overcoming Size & SUV? When Was Lung SBRT (stereotactic body…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
Aaron Logan, MD, Ph.D., Hematologist, Associate Professor of Clinical Medicine at UC San Francisco. In this video, he speaks about…
Aaron Logan, MD, Ph.D., Hematologist, Associate Professor of Clinical Medicine at UC San Francisco. In this video, he speaks about…
Daniel Herranz, PharmD, Ph.D., Assistant Professor in the Department of Pharmacology at the Robert Wood Johnson Medical School & Resident…
Daniel Herranz, PharmD, Ph.D., Assistant Professor in the Department of Pharmacology at the Robert Wood Johnson Medical School & Resident…
Craig Eagle, MD, FRACP, FRCPA from Guardant Health. In this video, he explains that the Study Shows Guardant360® Liquid Biopsy…
Dr. John Mascarenhas is a member of The Tisch Cancer Institute and a professor of medicine at Mount Sinai’s Icahn…
Bijal Shah, MD, MS, ZUMA-3 investigator, and medical oncologist, Moffitt Cancer Center, Tampa, Florida speaks about U.S. FDA Approves Kite’s…
Bijal Shah, MD, MS, ZUMA-3 investigator, and medical oncologist, Moffitt Cancer Center, Tampa, Florida speaks about U.S. FDA Approves Kite’s…
Somedeb Ball, MD from the H. Lee Moffitt Cancer Center & Research Institute speaks about Molecular annotation of extramedullary acute…
Anne L. Angiolillo, MD, MS, director of the Leukemia and Lymphoma Program at Children’s National Medical Center speaks about the…
Michael A. Pulsipher, MD from the Cancer and Blood Disease Institute, Children’s Hospital Los Angeles discusses Continued Role for Radiation…
Christina Peters, MD, Professor of Paediatrics of St. Anna Children’s Hospital, and the Children’s Cancer Research Institute speaks about Total…
Cutaneous T cell lymphoma (CTCL), a heterogeneous group of non-Hodgkin lymphomas is a rare but aggressive cancer that manifests primarily…
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Armon Sharei, Ph.D. Chief Executive Officer of SQZ…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma…
Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Aaron C.…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://www.naccme.com/program/19-lm-04 In this webcast from the ‘Recent Advances in Acute Leukemia Management’ symposium during the 2019 Lymphoma &…
Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA answers common questions on the characteristics and trends in adult acute…
Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA discusses the characteristics and trends in adult acute lymphoblastic leukemia. The…
Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223…
American doctor and cancer research scientist, Dr. William G. Kaelin, Jr. (Harvard University and Dana Farber Cancer Institute), along with…
Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses…
Eytan Stein, MD of @sloan_kettering discusses the first patient dosed in phase 1/2 AUGMENT-101 trial of SNDX-5613 for the treatment…
Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of…
National Comprehensive Cancer Network hosts summit on defining, measuring, and applying quality in an evolving health policy landscape and the…
Phase One Study Shows Novel KRAS Inhibitor Well Tolerated by Patients with Adenocarcinoma and Non-Small Cell Lung Cancer Barcelona–Sunday, September…
(9 September, Tokyo) In a recent study published in the journal Haematologica, researchers at Juntendo University used stem cell technology to…
Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to…
54% of 13 Evaluable Non-Small Cell Lung Cancer Patients Experienced a Partial Response at the Target Dose of 960 mg…
TORONTO, ON and LONDON, UK / ACCESSWIRE / September 6, 2019 /Â Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company discovering…
FINDINGS Breast cancer surgeons performing lumpectomies seek to spare healthy breast tissue while removing all cancerous cells, but determining appropriate…
Hamburg, Germany and Baltimore, Maryland, 2019.09.04 ̶ Using Sysmex Inostics’ novel SafeSEQ next- generation sequencing cell-free DNA technology, investigators from…
Yes. Screening techniques for ovarian cancer are nonexistent. Studies have looked at combinations of blood markers and ultrasounds, but they…
(Reuters Health) – Cancer specialists only rarely advise patients on lifestyle changes that could improve overall health and possibly also…
– Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one…
(New York, NY – September 3, 2019) – September is Thyroid Cancer Awareness Month,and doctors in the Mount Sinai Health System…
John Fruehauf, MD of UC Irvine Health discusses IMNC (International Neoadjuvant Melanoma Consoritum) Abstract 9503.
Afsaneh Barzi, MD of Keck School of Medicine discusses the immediate implications in the POLO trial is mandatory germline testing…
HATFIELD, Pa. and CLEVELAND, Aug. 27, 2019 /PRNewswire/ — Genisphere LLC and University Hospitals Cleveland Medical Center announced a partnership…
Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according…
Data from largest population study to date help identify at-risk individuals, could inform screening initiatives Published on: August 08, 2019 (WASHINGTON, August 8, 2019) — New…
Findings may guide decisions about which patients will benefit most from treatment with sorafenib Advanced hepatocellular carcinoma (HCC) is commonly…
TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. Also increased the time patients with central…
Adjuvant chemoradiotherapy improved overall survival for women with locally advanced endometrial cancer compared with radiation alone, a post-hoc analysis of…
NEW YORK — While new drugs for cancer are helping patients fight the disease, they also produce side effects that…
Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according…
TORONTO, CANADA / ACCESSWIRE / AUGUST 6, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, announced…
– Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors – First-in-class investigational therapy using autologous CAR-T cells…
— Enhanced survival outcomes in DKK1-high gastroesophageal junction and gastric cancer patients – — DKK1-high biomarker enables future patient selection –…
Early detection of HPV can prevent various forms of cancer in both men and women, including gay, transgender, and HIV-positive…
July 2, 2019 San Diego Supercomputer Center Researchers Find Novel Diagnosis Method  The invasive and expensive diagnosis process of…
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine,…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains…
Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School considers…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology addresses the policies proposed to drig pricing.
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology explains the role of CDK 4/6 inhibitors in…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the results of the ImPassion130, a phase…
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of…
New York, NY, June 28, 2019 – Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug…
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health discusses how impactful CAR-T cell therapy…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute explains the inhibitors currently being tested for…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Philadelphia, PA (June 4, 2019) – Oncoceutics, Inc. announced a publication in the Journal for ImmunoTherapy of Cancerdemonstrating ONC201 immunostimulatory activity…
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center explains the role of immuno-oncology (I-O) in the…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency discusses upcoming prostate cancer PARP inhibitor trials and…
Harold A. Burstein, M.D, discusses guideline updates on integration results from TAILORx. Use of Biomarkers to Guide Decisions on Adjuvant…
Thomas Yau MD, MBBS Of University of Hong Kong Discusses Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results…
Larissa Nekhlyudov MD MPH Of Brigham & Womens Hospital/Dana-Farber Cancer Institute, Harvard Medical School Discusses Bringing Primary Physician Back Into…
Geraldine O’ Sullivan Coyne, MD, discusses the Phase I Trial fo Murlentamab. Background: Membranous expression of AMHRII is found in…
Geraldine O’ Sullivan Coyne, MD, discusses the Phase I Trial of Murlentamab. Background: Membranous expression of AMHRII is found in…
Rod Humerickhouse discusses the Phase 3 CLL14 Trial. Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration targeted VenG…
Dr. Cora Sternberg Of Weill Cornell Medicine and NewYork-Presbyterian discusses results of the SAUL study. Background: Atezo, a monoclonal antibody…
Dr. Ronald Shcheff, MD, Of Weill Cornell Medicine and NewYork-Presbyterian discusses the results from KEYNOTE-001. Background: Pembrolizumab (pembro) monotherapy has…
Philadelphia, PA (May 17, 2019) – Oncoceutics, Inc. announced that the latest efficacy data for the use of ONC201 in…
Dr. Sanjay Popat discusses the quality of life for patients using Brigatinib. Background: Results from ALTA-1L (NCT02737501), an international, multicenter…
Dr. Sanjay Popat, PhD, disucsses the Phase 3 ALTA-1L sub-analyses. Background: We report an analysis of BRG vs CRZ in…
Background: MM patients (pts) with high cytogenetic risk have poor outcomes. In CASTOR, D-Vd prolonged progression-free survival (PFS) vs bortezomib…
Alexa Schrock, PhD, of Foundation Medicine Discusses High Microsatellite Instability (MSI-H) in Colorectal Carcinoma Study: Tumor mutational burden is predictive…
Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Safety Profile,…
Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy (PIT) Phase 2 Study: Multicenter, Open-Label, Study Of…
Marcus Butler, MD of Princess Margaret Cancer Centre discusses the ILLUMINATE 301 A randomized phase 3 study of tilsotolimod in…
Philadelphia, PA (May 7, 2019) – Oncoceutics announced that the US Food and Drug Administration invited the company to present…
The Eon Expert Series: Defying Lung Cancer with Eon + Mark Cuban Why does health tech hurt us more than…
 Philadelphia, PA (May 13, 2019) – Oncoceutics announced today that Michael Chiarella, an industry veteran with more than 20…
UCI team helps uncover how ‘FLASH radiotherapy’ reduces neural cell damage  Irvine, Calif., May 13, 2019 — In hopeful news…
UCI team helps uncover how ‘FLASH radiotherapy’ reduces neural cell damage  Irvine, Calif., May 13, 2019 — In hopeful news…
Philadelphia, PA (May 3, 2019) – Oncoceutics, Inc. announced the publication of two scientific research articles demonstrating that members of…
Composition of Matter Patent and Translational Research Grant issued for ONC213Philadelphia, PA (April 30, 2019) – Oncoceutics, Inc. announced that…
Philadelphia, PA (April 24, 2019) – Oncoceutics announced today that Accelerate Brain Cancer Cure (ABC2) has awarded a $116,523 grant…
NEW DATA SHOW BLUEPRINT® IDENTIFIES ESTROGEN RECEPTOR POSITIVE BREAST CANCER PATIENTS WITH POOR RESPONSE TO ANTI-ESTROGEN THERAPY WHO MAY BENEFIT FROM…
Philadelphia, PA (April 9, 2019) – Oncoceutics announced today the publication of an article entitled “First clinical experience with DRD2/3…
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million…
SOUTH SAN FRANCISCO, Calif., April 2, 2019 /PRNewswire/ –Â ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on the discovery…
April 02, 2019 08:00 ET | Source: Cybrexa Therapeutics   Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in…
Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of…
Laurence Albiges, Gustave Roussy Villejuif, France discusses HIF-2aa new target in metastatic RCCat the Kidney Cancer Association International Symposium 2019…
Toni K. Choueiri, MD of Dana-Farber Cancer Institute, Boston, MA discusses A First-in-Human Phase 1/2 Trial of the Oral HIF-2a…
Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active…
John B. Haanen MD PhD Department of Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital asks the question…
Oncoceutics Expands Patent Family to Include Composition of Matter for ONC206 in Europe  Philadelphia, PA (March 4, 2019) – Oncoceutics, Inc. announced…
John B. Haanen MD PhD gives the Fitzpatrick Memorial Lecture entitled Do we need a new Carmena in the IO…
Following the news on March 19, 2019 that Merck KGaA and Pfizer have discontinued the ongoing Phase III JAVELIN Ovarian…
AUBURNDALE, Mass., March 21, 2019 /PRNewswire/ – Candel Therapeutics (a.k.a. Advantagene, Inc.) announced today the treatment of the first high grade glioma patients in a…
(Kanazawa, 21 March 2019) Researchers at Kanazawa University report in Nature Communications what causes some lung-cancer patients to have an…
March 11, 2019 07:37 PM Eastern Daylight Time  NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced the United States…
On March 8, the FDA granted the accelerated approval of Roche’s programmed cell death protein 1 (PD-1) inhibitor Tecentriq in…
March 18, 2019 BOULDER, Colo., March 18, 2019 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National…
Philadelphia, PA (February 22, 2019) – Oncoceutics, Inc., announces the expansion of its diverse collaborations across the National Institutes of Health…
Read press release online:Â https://ir.moleculin.com/press-releases/detail/117/moleculin-files-with-fda-for-expedited-approval-pathway-for HOUSTON, TX- March 13, 2019 -Â Moleculin Biotech, Inc., (NASDAQ: MBRX)(“Moleculin” or the “Company”), a clinical stage…
Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combination Pembrolizumab And Olaparib In mCRPC. At…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combining Checkpoint Inhibitors In mCRPC. At The…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses How To Treat mRCC After Combination I-O In The…
Oncoceutics Licenses Rights to ONC201 for Japan to Ohara Pharmaceutical Co., Ltd. Philadelphia, PA (February 15, 2019) – Oncoceutics, Inc. announced…
(WASHINGTON, March 12, 2019) — Yesterday, President Donald Trump released a fiscal year 2020 budget request that proposes a 12…
Wood LS, Hoffner B, Rubin K, Davies MJ, Tushla LA, Guild V, Guild SR. Background Immune checkpoint inhibitors (ICIs) have…
Richard Finn, MD Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA discusses…
Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC…
Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC…
Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC…
Elizabeth Budde, MD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses CAR-T Therapy…
Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, Discusses…
James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Reliability Of The…
Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Outcomes Of The ECHELON-2 Study.…
Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses…
Nikhil Munshi, MD Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine,…
James McClosky, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Using Newly FDA…
Ravi Vij, MD Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Outcomes…
Nizar Bahlis, MD University of Calgary, Calgary, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on…
Nizar Bahlis, MD University of Calgary, Calgary, discusses Current Maintenance Regimens For MM. At The 60th ASH Annual Meeting on…
Samer Khaled, MD Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses Study Examining The…
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th…
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Outcomes Of The POLLUX And CASTOR Studies. At…
Carol Moreno, MD, PhD Hematologist, University of Barcelona, discusses Recent Advancements In The Treatment Of CLL. At The 60th ASH…
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen Discusses Anti-BCMA CAR-T Cell Therapy In MM. At The…
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses ALL As Second Cancer After Treatment, Explorative Study At The…
Pinkal Desai, M.D., Assistant Professor of Medicine Weill Cornell Medical College, Cornell University And Assistant Attending Physician at the New…
Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium,…
Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium,…
Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium,…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rob Pieters, MD, PhD, of Princess…
Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, outlines areas of improvement for treating chronic graft-versus-host…
By understanding the pathogenesis of chronic graft-versus-host disease (GvHD), treatments can be better targeted to improve patient outcomes. In this…
In this interview, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, makes predictions on what…
BMIC058
In this video, Robin Foà , MD, from the University of Rome, Rome, Italy, discusses the impact of age on patients…
Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, raises the issue of slow progression of clinical trials in acute…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Oliver Ottmann,…